A trial has compared a cancer chemotherapy to MS treatments, but further research is needed to understand how effective the treatment is in comparison to other MS treatments.
New research suggests the rate of brain atrophy, or brain shrinkage, may be an important indicator of disease progression in MS.
Interim results from one of the first randomised controlled trials comparing autologous haematopoietic stem cell transplant (AHSCT) to other MS therapies have been presented at a Lisbon conference.
Helmut Butzkueven, who led the development of MSBase with support from MS Research Australia, has received the Data Innovation Award.
Chronic Cerebrospinal Venous Insufficiency (CCSVI) describes a potential reduction in blood flow in the major veins that drain blood from the brain and spinal cord over a prolonged period.